Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.65 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7151959 | 1.00 | ESR2 (0.65) | ESR2SLC18A3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL7151961 | 1.00 | ESR2 (0.65) | ESR2SLC18A3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL27945820 | 0.94 | ESR2 (0.59) | ESR2SLC18A3KCNH2CYP3A4CYP2C9 | |
| SCHEMBL265495 | 0.88 | KDM1A (0.48) | ESR2KCNH2CYP3A4CYP2C9KDM1A | |
| SCHEMBL14804315 | 0.88 | KDM1A (0.48) | ESR2KCNH2CYP3A4CYP2C9KDM1A | |
| SCHEMBL3497539 | 0.87 | ESR2 (0.50) | ESR2KCNH2KDM1AMAOBRCOR1 | |
| SCHEMBL3496853 | 0.87 | ESR2 (0.50) | ESR2KCNH2KDM1AMAOBRCOR1 | |
| SCHEMBL5228850 | 0.87 | ESR2 (0.50) | ESR2KCNH2KDM1AMAOBRCOR1 | |
| SCHEMBL3497441 | 0.87 | ESR2 (0.50) | ESR2KCNH2KDM1AMAOBRCOR1 | |
| Methyl Alcohol SCHEMBL27656751 | 0.86 | ESR2 (0.50) | ESR2SLC18A3KCNH2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-B1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2020-04-29 | — | — | EP | disclosed |
| EP-3063148-A1 | AZABENZIMIDAZOLE DERIVATIVES | Boehringer Ingelheim International GmbH (DE) | 2016-09-07 | — | — | EP | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9187477-B2 | Azabenzimidazole derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015063011-A1 | AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119393-A1 | NEW AZABENZIMIDAZOLE DERIVATIVES | PRKAR2B, PRKAB2, PRKAB1 | ESR2 293/4885SLC18A3 4616/4885KCNH2 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.